- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ligelizumab more effective than Omalizumab in chronic spontaneous urticaria: Study
USA: Ligelizumab is more effective in reducing chronic spontaneous urticaria (CSU) severity compared with omalizumab, according to findings from a randomized, double-blind core study. The findings of the study were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience.
Jonathan Bernstein, the University of Cincinnati College of Medicine and Bernstein Clinical Research Center, and colleagues explored the shift of Weekly Urticaria Activity Score (UAS7) severity bands with ligelizumab treatment compared to omalizumab in patients with moderate or severe chronic spontaneous urticaria (UAS ≥16) at baseline.
For CSU disease activity UAS7 values were assigned to five score bands: UAS7=28─42 (severe); UAS7=16─27 (moderate); UAS7=7─15 (mild); UAS7=1─6 (well-controlled); UAS7=0 (urticaria-free). The researchers in the analysis presented the proportion of patients with either moderate or severe baseline CSU activity (UAS7≥16) achieving UAS7=0 at weeks 4, 12 (primary endpoint), and 20 (end of study) in the ligelizumab 72mg and 240mg arms, and the omalizumab 300mg arm (all dosed every 4 weeks).
Key findings of the study include:
- At baseline, the distribution of patients in moderate or severe CSU disease activity bands was similar across treatment arms (moderate, n[%]: ligelizumab 72mg=20[23.8]; ligelizumab 240mg=27[31.8]; omalizumab=32[37.6] | severe, n[%]: ligelizumab 72mg=63[75.0]; ligelizumab 240mg=56[65.9]; omalizumab=50[58.8]).
- For patients with moderate CSU, the proportion of patients on ligelizumab 72 and 240mg versus omalizumab achieving UAS7=0 at week─4 were 35.0% and 25.9% versus 12.5%, at week─12 were 60.0% and 40.7% versus 34.4%, and at week─20 were 45.0% and 37.0% versus 31.3%, respectively.
- For severe CSU patients, the proportion of patients on ligelizumab 72 and 240mg versus omalizumab achieving UAS7=0 at week─4 were 28.6% and 32.1% versus 22.0%, at week─12 were 38.1% and 41.1% versus 20.0%, and at week─20 were 38.1% and 42.9% versus 30.0%, respectively.
"With ligelizumab, high rates of complete urticaria response were observed consistently in both moderate and severe CSU patients," concluded the authors.
Reference:
The study titled, "High rate of complete response achieved with ligelizumab in patients with moderate to severe chronic spontaneous urticaria throughout the Phase 2b core study," was presented at AAD VMX 2021.
DOI: https://eposters.aad.org/abstracts/27362
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751